NEW YORK, Jan 30 – Rosetta Inpharmatics said Tuesday its fourth quarter net revenues increased to $5.6 million, compared with $386,000 a year ago, due to the launch of the Rosetta Resolver Gene Expression Data Analysis System, a collaboration agreement with Monsanto, and revenues from its partnership with Agilent.

For the full year, revenues increased more than 10-fold to $10.5 million, from $983,000 in 1999.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.